Novartis Receives EU Approval for Gene Therapy Luxturna (voretigene neparvovec) in Patients with Rare Inherited Retinal Disease

Shots:

• The approval is based on P-III trial, involving assesment of Luxturna vs control group patients, with inherited retinal disease (caused due to mutation in both copies of the RPE65 gene and sufficient viable retinal cells)
• Results: Vision improvement recorded @ 30 days following treatment, @1yr. MLMT (multi-luminance mobility test) (1.6); 65% patients successfully navigate the MLMT at the lowest light level of 1 lux
• Luxturna is gene therapy to restore vision is designed to provide a working copy of the RPE65 gene to act in place of the mutated RPE65 gene and currently marketed by Spark Therapeutics in the US

Click here to read full press release/ article | Ref: Novartis | Image: Pharmaceutical Technology